Great Debates and Updates in GI Malignancies

26. 3. 2010 - 27. 3. 2010, The Westin New York at Times Square, New York, New York, USA

Registrace

Program konference

Friday, March 26, 2010

7:00 am
Registration and Continental Breakfast

8:00 am
Welcome and introduction
Axel Grothey, MD and Daniel G. Haller, MD

Session I: Colorectal Carcinoma

8:10 am
Debate: Following a CR or near CR in advanced CRC from chemotherapy plus bevacizumab, is there significant value in continuing bev as maintenance therapy?

Yes, it improves and prolongs response
Cathy Eng, MD, FACP

No, it merely adds additional cost and toxicity
Howard S. Hochster, MD

8:40 am
Hereditary GI cancer syndromes: Advances in genetics, surveillance and management
Howard S. Hochster, MD

9:10 am
Debate: How intensively should resected CRC patients who have completed adjuvant therapy be followed?

High intensity surveillance
Al B. Benson III, MD, FACP

Low intensity surveillance
David P. Ryan, MD

9:40 am
Break

Session II: Hepato-Biliary Cancers

10:00 am
Debate: Is cisplatin-gemcitabine now the standard of care for advanced biliary tract cancer?

Yes, it is definitely the new standard
Ghassan K. Abou-Alfa, MD

Not so fast, we need confirmation of ABC-01/02 trials
David H. Ilson, MD, PhD

10:30 am
Debate: Have targeted agents significantly altered the long term outcome for advanced HCC?

Yes, they have achieved a major improvement in outcome
Ghassan K. Abou-Alfa, MD

No, only the best prognosis patients live a few extra months
Andrew X. Zhu, MD, PhD

11:00 am
What is the role of transarterial in HCC?
Karen T. Brown, MD

11:30 am
Novel therapies for advanced HCC: What to do when sorafenib fails?
Andrew X. Zhu, MD, PhD

12:00 pm
Lunch

Session III: Pancreatic Tumors

1:00 pm
Debate: What is the best adjuvant therapeutic approach for resected pancreatic carcinoma?

5-FU based adjuvant therapy
Jordan D. Berlin, MD

Gemcitabine based adjuvant therapy
David H. Ilson, MD, PhD

1:30 pm
Novel agents under development and evaluation for pancreatic adenocarcinoma: Molecular biology leading the way to novel therapeutics
Jordan D. Berlin, MD

2:00 pm
Neuroendocrine tumors: Recent advances and goals for the future
James C. Yao, MD

2:30 pm
Break

Session IV: Colorectal Carcinoma

3:00 pm
Debate: Can genomic and molecular markers stratify colon cancer patients by prognosis and predict response to therapy?

Yes
Al B. Benson III, MD, FACP

No
Daniel G. Haller, MD

3:30 pm
Debate: How should patients with resectable liver-only metastatic CRC be managed?

Neoadjuvant systemic therapy followed by surgery
John L. Marshall, MD

Surgery followed by adjuvant systemic therapy
Michael Choti, MD

4:00 pm
Debate: How should we manage resected stage III colon carcinoma in patients 70 years of age or older?

mFOLFOX6
Cathy Eng, MD, FACP

5-FU-leucovorin alone
Axel Grothey, MD

4:30 pm
Anal carcinoma: Standards of care, the role of HPV, vaccines and novel therapies under evaluation
Cathy Eng, MD, FACP

5:00 pm
Adjourn

Saturday, March 27, 2010

7:00 am
Registration and Continental Breakfast

8:00 am
Welcome and introduction
Axel Grothey, MD and Daniel G. Haller, MD

Session V: Gastro-Esophageal Adenocarcinoma

8:05 am
Debate What is the standard of care for adjuvant therapy of resected HER2-negative gastric and GE junction adenocarcinomas?

5-FU based chemoradiation
Jordan D. Berlin, MD

Combination chemotherapy alone
David H. Ilson, MD, PhD

8:35 am
Advanced gastro-esophageal HER2-positive adenocarcinoma: A case based discussion Three part clinical case beginning with neoadjuvant vs. adjuvant therapy discussion, followed by post adjuvant therapy recurrence, followed by management of post-trastuzumab recurrent disease
David P. Ryan, MD and Daniel G. Haller, MD

9:05 am
Break

Session VI: GIST

9:30 am
Debate: Does imatinib cure micro-metastases in resected GIST?

Yes
Lowell Anthony, MD

No
Robert Maki, MD, PhD

10:00 am
Debate: What is the most effective management of recurrent GIST?

Surgical resection followed by systemic therapy
Michael Choti, MD

Systemic therapy alone
Robert Maki, MD, PhD

Session VIII: Colon Carcinoma

10:30 am
Debate: Should oxaliplatin be added to the standard pre-op flouropyrimidines-XRT regimen for locally advanced rectal adenocarcinoma?

Yes, the benefit outweighs any added toxicity
David P. Ryan, MD

No, the additional toxicity outweighs the benefit
Christopher H. Crane, MD

11:00 am
Lunch

12:00 pm
Adjuvant therapy for resected colon cancer: Where do we stand now?
John L. Marshall, MD

12:30 pm
Novel targets and novel agents under development and evaluation for CRC
Lee M. Ellis, MD

1:00 pm
Debate: What should the role of RFA be in liver-only metastatic CRC?

RFA is underutilized
Karen T. Brown, MD, FSIR

RFA is over-utilized
Michael Choti, MD

2:30 pm
Debate: Is stage II colon cancer a different disease than stage III or merely an earlier stage of the same disease?

Stage II and III are biologically different diseases
Axel Grothey, MD

Stage II is an earlier stage of the same disease as stage III
John L. Marshall, MD

3:00 pm
Adjourn
Information coming soon.

Kontakt: meetings@imedex.com

Web: http://www.imedex...LMN_12_3_0912_3_20

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live